ATPase Type 13A4: A Promising Drug Target and Biomarker (G84239)

Target Name: ATP13A4

NCBI ID: G84239

ATP13A4

ATPase Type 13A4: A Promising Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the cell's energy metabolism. It is the primary energy carrier in muscle contraction, the main force of heartbeat, and the foundation of all cellular processes that require energy. The production and regulation of ATP is regulated by a complex network of enzymes, including ATPases. ATPases are transmembrane proteins that catalyze the conversion of ATP to ADP and Pi (phosphate) using ATP as a substrate. In this article, we discuss ATPase Type 13A4 (ATPase type 13A4), a protein that has emerged as a promising drug target and biomarker for various diseases.

Structure and Function

ATPase Type 13A4 is a 37-kDa protein that is expressed in most tissues and cells. The protein has a catalytic active site, a transmembrane region, and a cytoplasmic tail. The catalytic active site is the site of ATP binding and hydrolysis, and it is composed of multiple structural features, including a nucleotide-binding domain (NBD), a Rossmann-fold, and a hyperbolic tunnel.

ATPase Type 13A4 is involved in a wide range of cellular processes that require energy production and regulation. It is the catalytic subunit of the ATPase enzyme complex, which is responsible for generating ATP from ADP and Pi (phosphate). In addition to its role in energy metabolism, ATPase Type 13A4 is also involved in various signaling pathways, including the regulation of cell adhesion, migration, and survival.

Drug Target Potential

The drug targeting of ATPase Type 13A4 is based on its unique structure and function. Several studies have identified potential drug-like molecules that can interact with ATPase Type 13A4 and modulate its activity. One of these molecules, called P1, is a small molecule that can inhibit ATPase activity and decrease the production of ATP. Further analysis of the P1 molecule has revealed that it has a unique binding site on the ATPase active site that is distinct from other inhibitors.

Biomarker Potential

ATPase Type 13A4 is also a promising biomarker for various diseases due to its involvement in various cellular processes that are affected by dysfunctional energy metabolism. The dysregulation of ATPase Type 13A4 activity has been observed in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, the study of ATPase Type 13A4 as a biomarker may have implications for the development of new diagnostic tests and therapeutic strategies for these diseases.

Conclusion

In conclusion, ATPase Type 13A4 is a protein that is involved in a wide range of cellular processes that require energy production and regulation. Its unique structure and function make it an attractive drug target and biomarker for various diseases. The identification of potential drug-like molecules that can interact with ATPase Type 13A4 and modulate its activity supports the study of ATPase Type 13A4 as a promising drug target and biomarker. Further research is needed to fully understand the implications of ATPase Type 13A4 as a drug target and biomarker, and to develop new diagnostic tests and therapeutic strategies for various diseases.

Protein Name: ATPase 13A4

The "ATP13A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP13A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets